{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:09:34Z","timestamp":1785506974420,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The interrelationship between unemployment and substance use disorders, especially opioid use disorders, is complex, and basic epidemiological data are lacking both in Germany and elsewhere. This study aimed to evaluate the prevalence rates of opioid use disorder, work ability, and associated factors among unemployed individuals with opioid use disorder who underwent socio-medical assessment by the Medical Service (MS) of the Federal Employment Agency (FEA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All socio-medical assessments conducted between 2016 and 2021 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20094,249,028) were extracted from the FEA database and analyzed with respect to relevant sociodemographic characteristics, opioid use disorder (ICD-10 F11.x diagnosis) and work ability. Descriptive statistics were used to summarize the data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4,249,028 unemployed individuals were assessed. Of these, 22,683 clients (0.5%) met an F11.x diagnosis (primary or secondary); mostly opioid dependence (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200920,506; 94.3%). The number of diagnoses increased over time (2016\u20132021). Mean age was 40.7\u2009\u00b1\u20099.4 years. Overall, 15,065 (73.5%) were male and 5,441 (26.5%) were female. For individuals with a secondary diagnosis of F11.x, most frequent psychiatric comorbidities were alcohol dependence (27.8%), polysubstance use (17.6%), schizophrenia (8.8%), depression episode (8.3%) or recurrent depression (5.9%) and persistent pain disorder (6.1%). Regarding daily work capacity, 58.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911,962) of individuals were able to work less than 3\u00a0h per day, 10.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092,051) were able to work 3\u20136\u00a0h per day, and 17.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093,568) were able to work more than 6\u00a0h per day.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The number of unemployed individuals with opioid dependence in Germany has increased over time, and most are unable to work more than three hours per day. The most frequent psychiatric comorbidities were other substance use disorders, particularly alcohol use disorder, schizophrenia, and depression. Somatic comorbidities, with the exception of chronic viral hepatitis, were recorded less frequently. Tailored interventions and closer collaboration between employment agencies and mental health care providers are needed to improve the psychosocial integration of this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13011-026-00752-3","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:14:00Z","timestamp":1785341640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unemployment &amp; opioid use disorder \u2013 socio-medical assessment results by the Medical Service of the German Federal Employment Agency"],"prefix":"10.1186","volume":"21","author":[{"given":"Michael","family":"Soyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas G.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"10208","key":"752_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9.","journal-title":"Lancet"},{"key":"752_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04137-0","author":"J Kang","year":"2026","unstructured":"Kang J, Kim HJ, Kim MS, Collaborators GBDSU, Shin JI, Yon DK. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990\u20132023: a Global Burden of Disease Study. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-025-04137-0.","journal-title":"Nat Med"},{"key":"752_CR3","doi-asserted-by":"publisher","DOI":"10.18356\/9789210019545","volume-title":"World Drug Report 2022","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2022","unstructured":"United Nations Office on Drugs and Crime (UNODC). World Drug Report 2022. Vienna: UNODC; 2022."},{"key":"752_CR4","unstructured":"Institute for Health Metrics and Evaluation. GBD Compare: Opioid Use Disorders. University of Washington; 2024."},{"key":"752_CR5","first-page":"1","volume-title":"Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drig Use and Health","year":"2025","unstructured":"Administration SAaMHS. In: Quality, CfBHSa, editors. Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drig Use and Health. Rockville, MD: Substance Abuse and mental Health Services Administration; 2025. pp. 1\u2013132."},{"issue":"1","key":"752_CR6","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1186\/s12889-025-24541-y","volume":"25","author":"J Zhang","year":"2025","unstructured":"Zhang J, Liu R, Wang X, Zhang L, Pei W, Hou J, et al. Global burden, socioeconomic disparities, and spatiotemporal dynamics of opioid use disorder mortality and disability: a comprehensive analysis from the global burden of disease study 2017\u20132021. BMC Public Health. 2025;25(1):3254. https:\/\/doi.org\/10.1186\/s12889-025-24541-y.","journal-title":"BMC Public Health"},{"issue":"1","key":"752_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13011-017-0136-z","volume":"12","author":"DC Chang","year":"2017","unstructured":"Chang DC, Hadland SE, Nosova E, Wood E, Kerr T, DeBeck K. Socioeconomic factors associated with cessation of injection drug use among street-involved youth. Subst Abuse Treat Prev Policy. 2017;12(1):50. https:\/\/doi.org\/10.1186\/s13011-017-0136-z.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"752_CR8","doi-asserted-by":"crossref","unstructured":"French MT, Roebuck MC, Alexandre PK. Illicit drug use, employment, and labor force participation. South Econ J. 2001:68349\u201368.","DOI":"10.2307\/1061598"},{"issue":"3","key":"752_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1465-3362.2009.00141.x","volume":"29","author":"L Richardson","year":"2010","unstructured":"Richardson L, Wood E, Li K, Kerr T. Factors associated with employment among a cohort of injection drug users. Drug Alcohol Rev. 2010;29(3):293\u2013300. https:\/\/doi.org\/10.1111\/j.1465-3362.2009.00141.x.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"752_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jech-2013-202918","volume":"68","author":"LA Richardson","year":"2014","unstructured":"Richardson LA, Milloy MJ, Kerr TH, Parashar S, Montaner JS, Wood E. Employment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV care. J Epidemiol Community Health. 2014;68(1):93\u20136. https:\/\/doi.org\/10.1136\/jech-2013-202918.","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"752_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-017-0071-3","volume":"12","author":"M Chetty","year":"2017","unstructured":"Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addict Sci Clin Pract. 2017;12(1):6. https:\/\/doi.org\/10.1186\/s13722-017-0071-3.","journal-title":"Addict Sci Clin Pract"},{"key":"752_CR12","doi-asserted-by":"publisher","unstructured":"Dunne N, Casey MB, Ivers JH. What are the risk factors of non-fatal overdose among persons who use opioids? A systematic review and meta-analysis. J Subst Use Addict Treat. 2025:171209630. https:\/\/doi.org\/10.1016\/j.josat.2025.209630.","DOI":"10.1016\/j.josat.2025.209630"},{"issue":"4","key":"752_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","volume":"11","author":"YI Hser","year":"2017","unstructured":"Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, et al. High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. J Addict Med. 2017;11(4):315\u201319. https:\/\/doi.org\/10.1097\/ADM.0000000000000312.","journal-title":"J Addict Med"},{"issue":"1","key":"752_CR14","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/bmjopen-2011-000130","volume":"1","author":"I Skeie","year":"2011","unstructured":"Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, et al. Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study. BMJ Open. 2011;1(1):e000130. https:\/\/doi.org\/10.1136\/bmjopen-2011-000130.","journal-title":"BMJ Open"},{"key":"752_CR15","doi-asserted-by":"publisher","unstructured":"Bogdanowicz KM, Stewart R, Broadbent M, Hatch SL, Hotopf M, Strang J, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend. 2015:14885\u201392. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.12.025.","DOI":"10.1016\/j.drugalcdep.2014.12.025"},{"issue":"4","key":"752_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1360-0443.2007.02118.x","volume":"103","author":"KR Conner","year":"2008","unstructured":"Conner KR, Pinquart M, Duberstein PR. Meta-analysis of depression and substance use and impairment among intravenous drug users (IDUs). Addiction. 2008;103(4):524\u201334. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.02118.x.","journal-title":"Addiction"},{"issue":"1","key":"752_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11469-017-9784-5","volume":"16","author":"H Dauber","year":"2018","unstructured":"Dauber H, Braun B, Pfeiffer-Gerschel T, Kraus L, Pogarell O. Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany. Int J Ment Health Addict. 2018;16(1):66\u201380. https:\/\/doi.org\/10.1007\/s11469-017-9784-5.","journal-title":"Int J Ment Health Addict"},{"issue":"11","key":"752_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00127-015-1088-0","volume":"50","author":"DS Hasin","year":"2015","unstructured":"Hasin DS, Grant BF, The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015;50(11):1609\u201340. https:\/\/doi.org\/10.1007\/s00127-015-1088-0.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"752_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/add.15594","volume":"117","author":"YI Hser","year":"2022","unstructured":"Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, et al. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022;117(1):151\u201361. https:\/\/doi.org\/10.1111\/add.15594.","journal-title":"Addiction"},{"key":"752_CR20","doi-asserted-by":"publisher","unstructured":"Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019:19778\u201382. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.12.030.","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"752_CR21","doi-asserted-by":"publisher","unstructured":"Lai HM, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990\u20132014: A systematic review and meta-analysis. Drug Alcohol Depend. 2015:1541\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.05.031.","DOI":"10.1016\/j.drugalcdep.2015.05.031"},{"key":"752_CR22","first-page":"16","volume":"125","author":"M Lieb","year":"2010","unstructured":"Lieb M, Wittchen H-U, Palm U, Apelt SM, Siegert J, Soyka M. Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: Prevalence and impact on clinical features. Heroin Addict Relat Clin Probl. 2010;125:16.","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"4","key":"752_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/00048674251321272","volume":"59","author":"C Marel","year":"2025","unstructured":"Marel C, Siedlecka E, Wilson J, Eugene Dit Rochesson S, Chu D, Fisher A, et al. A systematic review and meta-analysis of the prevalence of alcohol and other drug use and problematic use among people accessing mental health treatment in Australia. Aust N Z J Psychiatry. 2025;59(4):361\u201377. https:\/\/doi.org\/10.1177\/00048674251321272.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"752_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1176\/appi.ajp.2012.12010112","volume":"170","author":"HM Pettinati","year":"2013","unstructured":"Pettinati HM, O\u2019Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12010112.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"752_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14656566.2025.2507124","volume":"26","author":"M Soyka","year":"2025","unstructured":"Soyka M. Approved medications for opioid use disorder: current update. Expert Opin Pharmacother. 2025;26(9):1055\u201369. https:\/\/doi.org\/10.1080\/14656566.2025.2507124.","journal-title":"Expert Opin Pharmacother"},{"key":"752_CR26","doi-asserted-by":"publisher","unstructured":"Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, et al. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021:228108996. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108996.","DOI":"10.1016\/j.drugalcdep.2021.108996"},{"issue":"5","key":"752_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jadohealth.2024.10.026","volume":"76","author":"JD Cance","year":"2025","unstructured":"Cance JD, Hairgrove S, Saavedra LM, Bonar EE, Walton MA, Patel SV, et al. Opioid Misuse and Suicide-Related Outcomes Among Adolescents and Young Adults: A Systematic Review. J Adolesc Health. 2025;76(5):781\u201397. https:\/\/doi.org\/10.1016\/j.jadohealth.2024.10.026.","journal-title":"J Adolesc Health"},{"issue":"1","key":"752_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2020;87(1):82\u20138. https:\/\/doi.org\/10.1016\/j.biopsych.2019.06.020.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"752_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hec.3286","volume":"26","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Chatterji P, Lahiri K. Effects of Psychiatric Disorders on Labor Market Outcomes: A Latent Variable Approach Using Multiple Clinical Indicators. Health Econ. 2017;26(2):184\u2013205. https:\/\/doi.org\/10.1002\/hec.3286.","journal-title":"Health Econ"},{"issue":"9","key":"752_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00127-021-02088-8","volume":"56","author":"U Guhne","year":"2021","unstructured":"Guhne U, Pabst A, Lobner M, Breilmann J, Hasan A, Falkai P, et al. Employment status and desire for work in severe mental illness: results from an observational, cross-sectional study. Soc Psychiatry Psychiatr Epidemiol. 2021;56(9):1657\u201367. https:\/\/doi.org\/10.1007\/s00127-021-02088-8.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"4","key":"752_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/acps.13067","volume":"140","author":"C Hakulinen","year":"2019","unstructured":"Hakulinen C, Elovainio M, Arffman M, Lumme S, Pirkola S, Keskimaki I, et al. Mental disorders and long-term labour market outcomes: nationwide cohort study of 2 055 720 individuals. Acta Psychiatr Scand. 2019;140(4):371\u201381. https:\/\/doi.org\/10.1111\/acps.13067.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"752_CR32","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00127-015-1097-z","volume":"50","author":"R Mojtabai","year":"2015","unstructured":"Mojtabai R, Stuart EA, Hwang I, Susukida R, Eaton WW, Sampson N, et al. Long-term effects of mental disorders on employment in the National Comorbidity Survey ten-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2015;50(11):1657\u201368. https:\/\/doi.org\/10.1007\/s00127-015-1097-z.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"752_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12995-022-00345-3","volume":"17","author":"U Guhne","year":"2022","unstructured":"Guhne U, Pabst A, Kosters M, Hasan A, Falkai P, Kilian R, et al. Predictors of competitive employment in individuals with severe mental illness: results from an observational, cross-sectional study in Germany. J Occup Med Toxicol. 2022;17(1):3. https:\/\/doi.org\/10.1186\/s12995-022-00345-3.","journal-title":"J Occup Med Toxicol"},{"issue":"1","key":"752_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1186\/s12889-019-7059-8","volume":"19","author":"GC Herber","year":"2019","unstructured":"Herber GC, Ruijsbroek A, Koopmanschap M, van der Proper K, Boshuizen H, et al. Single transitions and persistence of unemployment are associated with poor health outcomes. BMC Public Health. 2019;19(1):740. https:\/\/doi.org\/10.1186\/s12889-019-7059-8.","journal-title":"BMC Public Health"},{"key":"752_CR35","doi-asserted-by":"publisher","unstructured":"Franke AG, Schmidt P, Neumann S. Association between unemployment and mental disorders: a narrative update of the literature. Int J Environ Res Public Health. 2024;21(12). https:\/\/doi.org\/10.3390\/ijerph21121698.","DOI":"10.3390\/ijerph21121698"},{"key":"752_CR36","doi-asserted-by":"publisher","unstructured":"Nolte-Troha C, Roser P, Henkel D, Scherbaum N, Koller G, Franke AG. Unemployment and substance use: an updated review of studies from North America and Europe. Healthc (Basel). 2023;11(8). https:\/\/doi.org\/10.3390\/healthcare11081182.","DOI":"10.3390\/healthcare11081182"},{"key":"752_CR37","volume-title":"Monthly Report on Labour Market","author":"Federal Employment Agency (FEA)","year":"2026","unstructured":"Federal Employment Agency (FEA). Monthly Report on Labour Market. Nuremberg: Federal Employment Agency; 2026."},{"issue":"9","key":"752_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00103-024-03932-3","volume":"67","author":"AG Franke","year":"2024","unstructured":"Franke AG, Manz K, Lotz-Metz G. [Socio-medical assessment: an inventory of the Medical Service of the Federal Employment Agency]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024;67(9):1031\u201338. https:\/\/doi.org\/10.1007\/s00103-024-03932-3.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"752_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12889-025-21603-z","volume":"25","author":"P Roser","year":"2025","unstructured":"Roser P, Manz K, Scherbaum N, Lotz-Metz G, Franke AG. Prevalence of mental disorders and work ability among unemployed individuals in Germany: a register-based analysis of socio-medical assessments by the Federal Employment Agency between 2016 and 2021. BMC Public Health. 2025;25(1):475. https:\/\/doi.org\/10.1186\/s12889-025-21603-z.","journal-title":"BMC Public Health"},{"key":"752_CR40","doi-asserted-by":"publisher","unstructured":"Franke AG, Roser P, Scherbaum N, Pieper C, Manz K, Lotz-Metz G. Disease prevalence and working ability among socio-medically assessed unemployed people in Germany between 2016 and 2021: A secondary data analysis of the Federal Employment Agency. Public Health. 2025:24237\u201343. https:\/\/doi.org\/10.1016\/j.puhe.2025.02.021.","DOI":"10.1016\/j.puhe.2025.02.021"},{"issue":"1","key":"752_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0376-8716(","volume":"50","author":"M Kidorf","year":"1998","unstructured":"Kidorf M, Hollander JR, King VL, Brooner RK. Increasing employment of opioid dependent outpatients: an intensive behavioral intervention. Drug Alcohol Depend. 1998;50(1):73\u201380. https:\/\/doi.org\/10.1016\/s0376-8716(. 98)00005 \u2013 2.","journal-title":"Drug Alcohol Depend"},{"issue":"13\u201314","key":"752_CR42","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1081\/ja-200034591","volume":"39","author":"M Kidorf","year":"2004","unstructured":"Kidorf M, Neufeld K, Brooner RK. Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients. Subst Use Misuse. 2004;39(13\u201314):2215\u201338. https:\/\/doi.org\/10.1081\/ja-200034591.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"752_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10550887.2012.694604","volume":"31","author":"AB Laudet","year":"2012","unstructured":"Laudet AB. Rate and predictors of employment among formerly polysubstance dependent urban individuals in recovery. J Addict Dis. 2012;31(3):288\u2013302. https:\/\/doi.org\/10.1080\/10550887.2012.694604.","journal-title":"J Addict Dis"},{"key":"752_CR44","doi-asserted-by":"publisher","unstructured":"Leung J, Chan GCK, Tan SX, McClure-Thomas C, Degenhardt L, Hall W. State-level prevalence and associates of opioid dependence in the USA. Int J Environ Res Public Health. 2022;19(7). https:\/\/doi.org\/10.3390\/ijerph19073825.","DOI":"10.3390\/ijerph19073825"},{"key":"752_CR45","unstructured":"Dilling H, Mombour W, Schmidt MH. International Classification of Mental Disorders, 10th revision (ICD-10)."},{"key":"752_CR46","doi-asserted-by":"publisher","unstructured":"Meiler B, Franke AG, Scherbaum N, Rabl J. Psychiatric morbidity, utilization and quality of mental health care in long-term unemployed people. Int J Environ Res Public Health. 2023;20(6). https:\/\/doi.org\/10.3390\/ijerph20065066.","DOI":"10.3390\/ijerph20065066"},{"issue":"3","key":"752_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/10482911211048438","volume":"31","author":"J Rosen","year":"2021","unstructured":"Rosen J, Zelnick JR, Zoeckler J, Landsbergis P. Introduction to the Special Issue: Opioids and the Workplace - Risk Factors and Solutions. New Solut. 2021;31(3):201\u201309. https:\/\/doi.org\/10.1177\/10482911211048438.","journal-title":"New Solut"},{"issue":"9","key":"752_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3238\/arztebl.2019.0137","volume":"116","author":"L Kraus","year":"2019","unstructured":"Kraus L, Seitz NN, Schulte B, Cremer-Schaeffer P, Braun B, Verthein U, et al. Estimation of the Number of People With Opioid Addiction in Germany. Dtsch Arztebl Int. 2019;116(9):137\u201343. https:\/\/doi.org\/10.3238\/arztebl.2019.0137.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"752_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/10482911211043522","volume":"31","author":"R Imboden","year":"2021","unstructured":"Imboden R, Frey JJ, Bazell AT, Mosby A, Ware OD, Mitchell CS, et al. Workplace Support for Employees in Recovery From Opioid Use: Stakeholder Perspectives. New Solut. 2021;31(3):340\u201349. https:\/\/doi.org\/10.1177\/10482911211043522.","journal-title":"New Solut"},{"issue":"1","key":"752_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13011-019-0247-9","volume":"14","author":"J Reimer","year":"2019","unstructured":"Reimer J, Vogelmann T, Trumper D, Scherbaum N. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment. Subst Abuse Treat Prev Policy. 2019;14(1):57. https:\/\/doi.org\/10.1186\/s13011-019-0247-9.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"752_CR51","doi-asserted-by":"crossref","unstructured":"Neusser S, Trattner A, Pomorin N, Wasem J, Neumann A. Krankheitskosten der Opioid-Abh\u00e4ngigkeit in Deutschland. Suchtmedizin. 2020:22205\u201316.","DOI":"10.1055\/s-0041-1732163"},{"issue":"1","key":"752_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40273-024-01442-3","volume":"43","author":"P Chaudhary","year":"2025","unstructured":"Chaudhary P, Fadnes LT, Fosse S, Chalabianloo F, Johansson KA. Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation. PharmacoEconomics. 2025;43(1):93\u2013107. https:\/\/doi.org\/10.1007\/s40273-024-01442-3.","journal-title":"PharmacoEconomics"},{"key":"752_CR53","doi-asserted-by":"publisher","unstructured":"Appleby S, Al Musaimi O. Socioeconomic deprivation and opioid consumption: an analysis across England. Int J Environ Res Public Health. 2025;22(5). https:\/\/doi.org\/10.3390\/ijerph22050750.","DOI":"10.3390\/ijerph22050750"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-026-00752-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:23:21Z","timestamp":1785504201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13011-026-00752-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s13011-026-00752-3","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In compliance with the guidelines of the Federal Commissioner for Data Protection and Information Security (BfDI), the study data did not contain any personally identifiable information. The study was approved by the Data Protection Department of the FEA (Ref. No. AZ1400.12-1\/2023).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For the past five years MS has worked as a consultant for Camurus and Ethypharm. The other authors declare to have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}